Sagopilone is the first fully synthetic epothilone entered in clinical investigation for the treatment of solid tumors. Since peripheral sensory neuropathy is its major side effect, this study was aimed to provide a preclinical model to evaluate factors that might modulate this side effect. We investigated the general toxicity and the peripheral neurotoxicity of sagopilone administered with different doses and schedules in Wistar rats and we performed a PK/PD study. The aims of the study were to establish the effect of different infusion times (i.v. bolus, i.v. 30-min infusion, and i.v. 3-hr infusion) over a 4-week treatment period; to evaluate the effect on nerve conduction velocity (NCV), to assess whether these schedules have an impact on peripheral neurotoxicity; to allow PK/PD modelling during the first 24 hours after infusion After 2 weeks, a trend toward a different peripheral neurotoxicity (bolus > 30-min infusion > 3-hr infusion) could be assessed at the pathological and neurophysiological levels with both doses, but this trend was no longer present after 4 weeks. When sagopilone concentrations were measured in brain, sciatic nerve, liver and kidney a linear relationship with the PK parameters (AUC(0-24h), Cmax) was observed. Sagopilone concentrations in sciatic nerve above 100 ng/g 24 hr after the 4th administration were associated with a reduction in NCV. A clear dose-dependence of NCV reduction on the level of systemic exposure was not observed but there was a time- dependence with more severe effects after 4 weeks. Both infusion duration of sagopilone had no consistent effect on PK parameters and on NCV; however, bolus was associated with higher AUC. Although lowest mean NCV values were observed at highest AUC values after 2 weeks, this relationship between AUC or Cmax and NCV impairment was no longer evident at the end of the study. Cmax and AUC values had a significant correlation across the study, therefore, the Cmax – NCV relationship was very similar to the AUC – NCV data. In conclusion, this study shows that the combination of neuropathological and neurophysiological investigations should be associated with PK/PD studies to obtain a better insight in the time course and severity of the peripheral neurotoxicity of sagopilone.
Chiorazzi, A., Oggioni, N., Meregalli, C., Avezza, F., RODRIGUEZ MENENDEZ, V., Lewin, R., et al. (2011). Effect of different chronic treatment modalities on the peripheral neurotoxicity of sagopilone in rats: a multimodal analysis. In Peripheral Nerve Society 2011 Biennial Meeting (pp.22-23). WILEY-BLACKWELL.
Effect of different chronic treatment modalities on the peripheral neurotoxicity of sagopilone in rats: a multimodal analysis
CHIORAZZI, ALESSIAPrimo
;OGGIONI, NORBERTOSecondo
;MEREGALLI, CRISTINA;AVEZZA, FEDERICA;RODRIGUEZ MENENDEZ, VIRGINIA;CAVALETTI, GUIDO ANGELOUltimo
2011
Abstract
Sagopilone is the first fully synthetic epothilone entered in clinical investigation for the treatment of solid tumors. Since peripheral sensory neuropathy is its major side effect, this study was aimed to provide a preclinical model to evaluate factors that might modulate this side effect. We investigated the general toxicity and the peripheral neurotoxicity of sagopilone administered with different doses and schedules in Wistar rats and we performed a PK/PD study. The aims of the study were to establish the effect of different infusion times (i.v. bolus, i.v. 30-min infusion, and i.v. 3-hr infusion) over a 4-week treatment period; to evaluate the effect on nerve conduction velocity (NCV), to assess whether these schedules have an impact on peripheral neurotoxicity; to allow PK/PD modelling during the first 24 hours after infusion After 2 weeks, a trend toward a different peripheral neurotoxicity (bolus > 30-min infusion > 3-hr infusion) could be assessed at the pathological and neurophysiological levels with both doses, but this trend was no longer present after 4 weeks. When sagopilone concentrations were measured in brain, sciatic nerve, liver and kidney a linear relationship with the PK parameters (AUC(0-24h), Cmax) was observed. Sagopilone concentrations in sciatic nerve above 100 ng/g 24 hr after the 4th administration were associated with a reduction in NCV. A clear dose-dependence of NCV reduction on the level of systemic exposure was not observed but there was a time- dependence with more severe effects after 4 weeks. Both infusion duration of sagopilone had no consistent effect on PK parameters and on NCV; however, bolus was associated with higher AUC. Although lowest mean NCV values were observed at highest AUC values after 2 weeks, this relationship between AUC or Cmax and NCV impairment was no longer evident at the end of the study. Cmax and AUC values had a significant correlation across the study, therefore, the Cmax – NCV relationship was very similar to the AUC – NCV data. In conclusion, this study shows that the combination of neuropathological and neurophysiological investigations should be associated with PK/PD studies to obtain a better insight in the time course and severity of the peripheral neurotoxicity of sagopilone.File | Dimensione | Formato | |
---|---|---|---|
PNS Sagopilone_inviato.pdf
accesso aperto
Dimensione
8.67 kB
Formato
Adobe PDF
|
8.67 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.